CoChat

A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence

Dackis, Charles A, Kampman, Kyle M, Lynch, Kevin G, Pettinati, Helen M, O'Brien, Charles P · 2005 · Neuropsychopharmacology

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Abstract

Despite years of active research, there are still no approved medications for the treatment of cocaine dependence. Modafinil is a glutamate-enhancing agent that blunts cocaine euphoria under controlled conditions, and the current study assessed whether modafinil would improve clinical outcome in cocaine-dependent patients receiving standardized psychosocial treatment. This was a randomized, double-blind, placebo-controlled trial conducted at a university outpatient center (from 2002 to 2003) on a consecutive sample of 62 (predominantly African American) cocaine-dependent patients (aged 25-63) free of significant medical and psychiatric conditions. After screening, eligible patients were randomized to a single morning dose of modafinil (400 mg), or matching placebo tablets, for 8 weeks while receiving manual-guided, twice-weekly cognitive behavioral therapy. The primary efficacy measure was cocaine abstinence based on urine benzoylecgonine levels. Secondary measures were craving, cocaine withdrawal, retention, and adverse events. Modafinil-treated patients provided significantly more BE-negative urine samples (p=0.03) over the 8-week trial when compared to placebos, and were more likely to achieve a protracted period (> or =3 weeks) of cocaine abstinence (p=0.05). There were no serious adverse events, and none of the patients failed to complete the study as a result of adverse events. This study provides preliminary evidence, which should be confirmed by a larger study, that modafinil improves clinical outcome when combined with psychosocial treatment for cocaine dependence.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.npp.1300600

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 43 references

Research works printed but not linked: 4

  1. First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis I Disorders—Subject Edition (SCID-I/P, Version 2.0). Biometrics Research Department New York State Psychiatric Institute: New York.
  2. Kadden R, Carroll K, Donovan D, Cooney N, Monti P, Abrams D et al (1992). Cognitive-Behavioral Coping Skills Therapy Manual. US Government Printing Office: Washington, DC.
  3. Malcolm RJ, Donovan JL, DeVane CL, Elkashef A, Chiang N, Mojsiak J (2002). Influence of Modafinil, 400 or 800 mg/day on Subjective Effects of Intravenous Cocaine in Non-treatment Seeking Volunteers. College on Problems of Drug Dependence: Quebec City.
  4. Somoza E, Dyrenforth S, Goldsmith J, Mezinskis J, Cohen M (1995). In search of a Universal Drug Craving Scale. Annual Meeting of the American Psychiatric Association: Miami, FL.

Cited by

Items 301–391 of 391

Metadata

Authors
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P.
Affiliations
University of Pennsylvania (US)
Corresponding author
Dackis, Charles A
Venue
Neuropsychopharmacology
Published
2004-11-03
Volume
30
Issue
1
Pages
205-211
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W1966136869
Cited by
391
References
44
Citations by year
2026: 3 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 9 · 2021: 13 · 2020: 2 · 2019: 10 · 2018: 6 · 2017: 8 · 2016: 21 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 26
FWCI
19.17
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5p60da005186-25)
  • National Institute on Drug Abuse (DA P60-05186, DA P50-12756, P50DA012756)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
modafinil, cocaine dependence, cocaine abstinence, cognitive behavioral therapy, psychosocial interventions, cocaine craving, cocaine withdrawal, medication-assisted treatment, African American patients
MeSH terms
Modafinil, Adult, Central Nervous System Stimulants, Benzhydryl Compounds, Double-Blind Method, Female, Humans, Male, Middle Aged, Patient Compliance, Psychiatric Status Rating Scales, Substance Withdrawal Syndrome, Treatment Outcome, Sample Size, Cocaine-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.